# Iridex Corp: overview IRIX · Nasdaq · CIK 1006045 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 3 Pages: [Overview](/companies/irix.md) · [Financials](/companies/irix/financials.md) · [Filings](/companies/irix/filings.md) · [Insiders](/companies/irix/insiders.md) Latest reported revenue: [$12.6m](/filings/0001193125-26-355641.md) for Q2 FY2026, three months to 2026-07-04, from the 10-Q filed Aug 18, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-355641). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.6](/filings/0001193125-25-277712.md) | [12.7 d](/filings/0001193125-26-140194.md) | [11.9](/filings/0001193125-26-230789.md) | [13.6](/filings/0001193125-26-355641.md) | [12.5](/filings/0001193125-25-277712.md) | [14.7 d](/filings/0001193125-26-140194.md) | [11.8](/filings/0001193125-26-230789.md) | [12.6](/filings/0001193125-26-355641.md) | | Gross margin | % | [37.3%](/filings/0001193125-25-277712.md) | [44.0% d](/filings/0001193125-26-140194.md) | [42.5%](/filings/0001193125-26-230789.md) | [34.5%](/filings/0001193125-26-355641.md) | [32.1%](/filings/0001193125-25-277712.md) | [37.2% d](/filings/0001193125-26-140194.md) | [40.2%](/filings/0001193125-26-230789.md) | [34.2%](/filings/0001193125-26-355641.md) | | Operating margin | % | [(16.1%)](/filings/0001193125-25-277712.md) | [(4.0%) d](/filings/0001193125-26-140194.md) | [(1.7%)](/filings/0001193125-26-230789.md) | [(6.9%)](/filings/0001193125-26-355641.md) | [(11.3%)](/filings/0001193125-25-277712.md) | [(0.1%) d](/filings/0001193125-26-140194.md) | [(2.7%)](/filings/0001193125-26-230789.md) | [(8.2%)](/filings/0001193125-26-355641.md) | | Net margin | % | [(16.7%)](/filings/0001193125-25-277712.md) | [(6.6%) d](/filings/0001193125-26-140194.md) | [(14.2%)](/filings/0001193125-26-230789.md) | [(7.3%)](/filings/0001193125-26-355641.md) | [(12.6%)](/filings/0001193125-25-277712.md) | [(1.2%) d](/filings/0001193125-26-140194.md) | [(4.4%)](/filings/0001193125-26-230789.md) | [(10.1%)](/filings/0001193125-26-355641.md) | | Diluted EPS | $ per share | [(0.12)](/filings/0001193125-25-277712.md) | not reported | [(0.10)](/filings/0001193125-26-230789.md) | [(0.06)](/filings/0001193125-26-355641.md) | [(0.09)](/filings/0001193125-25-277712.md) | not reported | [(0.03)](/filings/0001193125-26-230789.md) | [(0.07)](/filings/0001193125-26-355641.md) | | Free cash flow | $m | [(3.1) d](/filings/0001193125-25-277712.md) | [(1.2) d](/filings/0001193125-26-140194.md) | [(1.2)](/filings/0001193125-26-230789.md) | [(0.4) d](/filings/0001193125-26-355641.md) | [(1.2) d](/filings/0001193125-25-277712.md) | [0.5 d](/filings/0001193125-26-140194.md) | [(1.4)](/filings/0001193125-26-230789.md) | [0.1 d](/filings/0001193125-26-355641.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2022-01-01) | FY2022 (2022-12-31) | FY2023 (2023-12-30) | FY2024 (2024-12-28) | FY2025 (2026-01-03) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [53.9](/filings/0000950170-23-007061.md) | [57.0](/filings/0000950170-24-038650.md) | [51.9](/filings/0000950170-25-046107.md) | [48.7](/filings/0001193125-26-140194.md) | [52.7](/filings/0001193125-26-140194.md) | | Gross margin | % | [42.4%](/filings/0000950170-23-007061.md) | [44.5%](/filings/0000950170-24-038650.md) | [42.0%](/filings/0000950170-25-046107.md) | [40.1%](/filings/0001193125-26-140194.md) | [36.5%](/filings/0001193125-26-140194.md) | | Operating margin | % | [(14.0%)](/filings/0000950170-23-007061.md) | [(13.2%)](/filings/0000950170-24-038650.md) | [(19.3%)](/filings/0000950170-25-046107.md) | [(17.1%)](/filings/0001193125-26-140194.md) | [(4.9%)](/filings/0001193125-26-140194.md) | | Net margin | % | [(9.7%)](/filings/0000950170-23-007061.md) | [(13.2%)](/filings/0000950170-24-038650.md) | [(18.5%)](/filings/0000950170-25-046107.md) | [(18.3%)](/filings/0001193125-26-140194.md) | [(8.4%)](/filings/0001193125-26-140194.md) | | Diluted EPS | $ per share | [(0.34)](/filings/0000950170-23-007061.md) | [(0.47)](/filings/0000950170-24-038650.md) | [(0.59)](/filings/0000950170-25-046107.md) | [(0.54)](/filings/0001193125-26-140194.md) | [(0.26)](/filings/0001193125-26-140194.md) | | Free cash flow | $m | [8.0](/filings/0000950170-23-007061.md) | [(9.8)](/filings/0000950170-24-038650.md) | [(6.9)](/filings/0000950170-25-046107.md) | [(7.3)](/filings/0001193125-26-140194.md) | [(2.3)](/filings/0001193125-26-140194.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/irix/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE](/funds/1047859.md) | 2026-03-31 | $1.0m | 1,000,000 | | Not compared | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $589.2k | 514,593 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $485.0k | 423,542 | | Added +26,915 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $349.4k | 305,193 | | New +305,193 | | [WEBER CAPITAL MANAGEMENT LLC /ADV](/funds/1099905.md) | 2026-06-30 | $206.6k | 180,451 | | Reduced −79,107 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $159.2k | 138,960 | | Reduced −21,199 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $113.3k | 98,950 | | Added +38,099 | | [PERKINS CAPITAL MANAGEMENT INC](/funds/884300.md) | 2026-06-30 | $81.1k | 70,800 | | Added +15,500 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $68.9k | 60,155 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $51.2k | 44,718 | | Unchanged | ## Recent filings [All 928 filings](/companies/irix/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-02 | 20:20 ET | [8-K](/filings/0001193125-26-380229.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001193125-26-380229 | | 2026-08-18 | 20:54 ET | [10-Q](/filings/0001193125-26-355641.md) | Quarterly report, period 2026-07-04 | 0001193125-26-355641 | | 2026-08-18 | 20:51 ET | [8-K](/filings/0001193125-26-355635.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-355635 | | 2026-07-16 | 10:01 ET | [8-K](/filings/0001193125-26-305344.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-305344 | | 2026-07-13 | 21:49 ET | [SCHEDULE 13D/A](/filings/0002064835-26-000078.md) | Ownership report, active investor, amended | 0002064835-26-000078 | | 2026-06-18 | 20:14 ET | [8-K](/filings/0001193125-26-275883.md) | 8.01 Other events | 0001193125-26-275883 | | 2026-05-19 | 20:16 ET | [10-Q](/filings/0001193125-26-230789.md) | Quarterly report, period 2026-04-04 | 0001193125-26-230789 | | 2026-05-19 | 20:13 ET | [8-K](/filings/0001193125-26-230774.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-230774 | | 2026-04-24 | 20:05 ET | [DEF 14A](/filings/0002077096-26-000092.md) | Proxy statement, period 2026-06-12 | 0002077096-26-000092 | | 2026-04-02 | 20:20 ET | [10-K](/filings/0001193125-26-140194.md) | Annual report, period 2026-01-03 | 0001193125-26-140194 | ## Latest annual report [Form 10-K for the fiscal year ended Jan 3, 2026](/filings/0001193125-26-140194.md), filed Apr 2, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1006045 - Tickers: IRIX - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.